



ASX MEDIA RELEASE

Uscom releases new hypertension product BP+ Reporter

SYDNEY, Australia, Thursday 2nd August 2018: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) announced the release of its new BP+ Reporter hypertension product. The BP+ Reporter is a companion application that runs on a PC and interfaces with the Uscom BP+ suprasystolic oscillometric blood pressure (BP) monitor. The BP+ Reporter provides novel patient archiving, image storage, analysis, parametric trending and reporting of BP data, and has been in development by Uscom for over 3 years.

While existing BP monitors report 3-4 measures and no pulse pressure waveforms, the BP+ and BP+ Reporter measure and store over 25 parameters of cardiovascular function, and three pulse pressure waveforms from the heart, aorta and the arm from each 45 second measure. This additional data provide unique diagnostic and analytic capabilities that can be used to improve the management and understanding of hypertension. The BP+ and BP+ Reporter create a new clinical benchmark for advanced cardiovascular monitoring and can digitally interface with electronic medical record systems.

The Uscom BP+ technology is patent protected and is currently being rolled out as regional regulatory approvals permit. Revenue is beginning and is expected to accelerate throughout FY 2019. The Uscom BP+ received CE Mark in December 2017, while Chinese CFDA and US FDA submissions are currently in process with certification expected over the next 12 months. Release of the BP+ Reporter means it complies with all Uscom internal quality processes and can proceed through independent regulatory review with the BP+ submissions.

Uscom CEO Associate Professor Rob Phillips said: *"The BP+ Reporter further establishes Uscom as sector leaders in the field of hypertension. Hypertension is common, dangerous, expensive and poorly managed, with new studies suggesting central BP, as measured by the BP+, significantly improves diagnosis and management of BP, and is expected to improve patient compliance. The BP+ Reporter puts the "+" into BP monitoring and hypertension management, and changes the way we look at the disease. Professor Julio Chirinos, the VP of the North American Artery society and an Associate Professor at the University of Pennsylvania School of Medicine, is utilising the BP+ technology in a number of research projects including eHealth for heart failure. The patented BP+ system will potentially revolutionise hypertension diagnosis and management, and we are looking forward to receiving the certifications that will allow free sale of the BP+ into global markets."*

Hypertension facts:

1. 40% of over 25 year olds worldwide have hypertension
2. 50% of those with hypertension are unaware they have hypertension
3. 75% of those with hypertension are not treated effectively
4. 10M lives are lost annually to hypertension
5. \$375B spent annually on hypertension with \$100B potential saved with effective treatment
6. \$100M lives can potentially be saved with effective treatment

References:

Moran AE, Odden MC, Thanataveerat A, et al. Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines. N Engl J Med 2015; 372:447-455. DOI: 10.1056/NEJMsa1406751
Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation 2016;134:441-450. Doi.org/10.1161/CIRCULATIONAHA.115.018912
Frieden TR, Jaffe MG. Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors. J Clin Hypertens 2018. <https://doi.org/10.1111/jch.13195>



ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse pulse pressure waves and generate a summary report.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone applications and proprietary SpiroSonic software platforms with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial lung disease and monitoring of pulmonary therapeutic compliance. The SpiroSonic devices are supported by the proprietary **SpiroReporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations, trend measure progress over time, analyse spirometry outputs and generate a summary report.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary
secretary@uscom.com.au